Lecanemab
-
Add Alzheimer’s drug lecanemab to Canada’s public drug plans, agency saysLecanemab is an antibody that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of the disease.HealthJul 16
-
‘This is a big deal’: Health Canada approves 1st drug to slow Alzheimer’s diseaseThe treatment, lecanemab, has already been approved in some other countries, including the U.S., the U.K., Japan, Mexico and China.CanadaOct 29, 2025
-
Experimental Alzheimer’s drug slows disease, researchers say. Will it make a difference?An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening, researchers reported Tuesday.HealthNov 30, 2022
![]()
